Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Articles: DFG German National Licenses  (2)
  • C-peptide  (1)
  • Clinical experience  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles (1991)
    Springer
    European journal of clinical pharmacology 41 (1991), S. 263-265 
    Details
    ISSN: 1432-1041
    Keywords: Metformin ; Glibenclamide ; NIDDM ; lipoproteins ; C-peptide ; diabetes mellitus ; adverse effects ; serum lipids
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary. Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year. The drugs had an equivalent effect on glycaemic control, but, in contrast to glibenclamide, metformin reduced body weight. Neither drug affected triglycerides, total-and LDL-cholesterol or C-peptide. Metformin caused a slight elevation of HDL-cholesterol (P 〈 0.05). No serious adverse effects were observed. The results show that oral hypoglycaemic agents are not associated with undesirable effects on lipids and lipoproteins.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00315441
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Preclinical safety assessment of contrast media: predictive value (1996)
    Springer
    European radiology 6 (1996), S. S3 
    Details
    ISSN: 1432-1084
    Keywords: Contrast media ; Preclinical safety assessment ; Clinical experience
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The purpose of preclinical tests is to identify the potential benefits and risks of new diagnostic or therapeutic products. Regarding iodinated contrast media (CM), LD50 tests were used extensively in the past. However, from both scientific and ethical perspectives it is today highly relevant to question the use of LD50 tests. Due to species differences and the very high volume of CM needed to kill half of the animals, such tests are not sensitive enough to differentiate between modern nonionic CM. Further, they are not very predictive in terms of human tolerability. In other tests with more relevant end-points than death, overall tolerance to the new dimeric compound iodixanol (Visipaque), representing the latest step in the development of CM, has been shown to be higher than to tire nonionic monomers. Clinical experience has shown that the physiological parameters often stay closer to baseline alter Visipaque than after administration of conventional CM.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02342564
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...